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Introduction
The first human coronavirus was discovered in 1960 and was 
responsible for upper respiratory tract infection. Since then, two 
major pandemics have afflicted humanity: SARS-CoV Epidemic 
(2003) and MERS-CoV (2013).1 At the end of December 2019, a 
new disease of unknown aetiology appeared in Wuhan, China.2 The 
World Health Organization (WHO), on March 11, 2020, declared the 
novel coronavirus (COVID-19) outbreak a global pandemic.3 Last 
year, governments, universities, and industries made a huge effort 
to develop a vaccine. In September 2020, there were 321 candidate 
vaccines; of these, 33 were tested in clinical trials.4 By the end of 
2020, a few vaccines were available, and at the beginning of 2021 
more were forthcoming. The two vaccines produced by Pfizer and 
Moderna have a special requirement – they need to be stored at a 
very low temperature.5 The University of Oxford and Astra Zeneca 
created a vaccine of6 that can be stored at normal fridge temperatures. 
Before the end of 2020, the vaccination campaign started in some 
countries, and by March 18, 2021, more than 400 million people 
living worldwide received their first COVID jab. 
Since the development of these vaccines, their efficacy and 
comparison have become a frequent subject of discussion in the 
media and scientific publications; comments and editorials have 
appeared in many journals such as the British Medical Journal.7 We 
felt the need to clarify, with simple examples, how efficacy can be 
calculated and compared across vaccines. We aimed to be consistent 
with the existing guidelines for reporting trials results, such as the 
Consolidated Standards of Reporting Trials (CONSORT) statement.8 
Hodgson et al. 2021, in their publication in the Lancet, provided 
several definitions of efficacy according to different study endpoints.9 
In recent news reports, we might hear that a new COVID vaccine is 
“95% effective” and regard this as very good without having a clear 
idea of just what it means. This article aims to explain the term and 
how to calculate it. We should also explain what this article is not. It is 
not a comprehensive checklist for reporting a vaccine trial, comparable 
to CONSORT. It deals with numerical results only, not with problems 
of selecting subjects from a target population, the safety of a vaccine, 
finding suitable comparators (particularly older subjects during an 
epidemic, for whom participation would itself involve risk); nor do 
we deal with adverse outcomes.
Aim: To provide simple and clear guidance for calculating, 
interpreting, and reporting the numerical results of vaccine trials. 
Before looking at the examples, we introduce an item checklist 
summarising the most important information that should be reported 
in the results section of a clinical trial using a tabular format for clarity 
and simplicity (Table 1). 
Statistical meaning of 95% efficacy and confidence 
interval
Some people might think that 95% efficacy means that 95 out of 
every 100 people given the vaccine will not develop the infection. 
But this could happen even without a vaccine or placebo, particularly 
in younger people. Therefore, it cannot be the real meaning. We can 
explain this concept using the subjects in a two-arm randomised 
controlled clinical trial. One arm of the trial receives the vaccine, the 
other (control) the placebo. Treatments are allocated randomly, and 
large numbers of patients are recruited to make the arms similar in 
every way except for the treatments. In a trial with equal-sized arms, 
our estimate for efficacy would be the fraction of cases in the control 
arm that the vaccine prevented in the experimental arm. The sizes 
of trial arms will not usually be exactly equal, however, and a more 
comprehensive definition is the proportionate reduction in risk in the 
vaccine arm. We also need to report the uncertainty in our estimate of 
“efficacy.” To calculate the confidence interval, we can use the fact 
that vaccine efficacy is 1 minus the relative risk (RR) of infection 
in the vaccinated group. We can easily obtain a confidence interval 
for log (RR) using standard formulae for its standard error. However, 
even an apparent result of 100% efficacy needs to be assessed with 
due caution. Applying the “rule of 3,” a confidence interval for an 
estimate for a proportion of events, given zero occurring out of n has 
an upper limit of 3/n. Thus, if zero cases occurred out of 100, the 
upper limit confidence interval for the proportion would be about 3%, 
not 0%. For our purposes, the complement of this proportion would 
correspond to the proportion protected, which is the effectiveness. 
Hence the lower limit of the confidence interval for the efficacy would 
be about 97%, not 100%.
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Abstract
In one year, the COVID pandemic has changed the world. Universities, pharmaceutical 
companies, and many other organisations worldwide worked effortlessly to develop 
vaccines to ease the socioeconomic burden of the disease and improve global health care. 
Nowadays, vaccine efficacy is a very popular term; but do we know what it means and 
how to calculate it? This article provides information on reporting and interpreting the 
numerical results of a vaccine trial. It aims to be a practical guide for students and health 
care professionals. It gives a simple definition of the common terminology, the vaccine 
efficacy, how to calculate it, and how the confidence interval can be found (though formulae 
for the latter are not given here). Additionally, it provides two simple examples (A, B), 
including the formulae for calculating the vaccine efficacy explaining the differences of 
vaccine efficacy between the two examples simply and pragmatically.
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Table 1 Terminology used for reporting numerical results of a vaccine trial
Item Abbreviation Definition
Control event rate CER The proportion of patients in the control group who experience the studied event.
Experimental event rate EER The proportion of patients in the experimental treatment group who are observed to 
experience the outcome of interest.
Relative Risk RR
The risk of the outcome in the intervention group compared to the risk in the 
control group.
Absolute risk reduction ARR The difference in risk between the control group and the treatment group.
Number needed to treat 
(adverse outcomes) NNT
A measure of treatment efficacy/effectiveness. It is the average number of people 
who need to be treated with a specific intervention for a given period to prevent one 
additional adverse outcome. 
Vaccine efficacy VE
The percentage reduction in disease risk in a vaccinated group compared to a non-
vaccinated group under optimal conditions (RCT).
Vaccine effectiveness VE It is the percentage reduction in disease risk in a vaccinated group compared to a non-vaccinated group in real-world conditions. 
Guide for reporting numbers on vaccine trials statistics
We consider two examples, presented in Table 2 & 3. In the 
examples, we used two-arm trials with equal numbers. Table 2 shows 
the calculations for vaccine A versus placebo, which has an efficacy 
of 95%. Table 3 shows the estimates for vaccine B versus placebo, 
which has an efficacy of 90%. In the tables, there are three numbers 
highlighted in bold: 
I. The number of infected patients in the intervention group;
II. The number needed to treat (NNT) to obtain one immune 
patient; 
III. The efficacy expressed as a percentage.
What are these numbers telling us?
The number of infected patients is lower in the population 
vaccinated with A (n=5) (Table 2) than B (n=10) (Table 3). The 
difference is that 5 (=10-5) more patients were infected in the Vaccine 
B group. The NNT, however, is more helpful, as it is the number of 
patients that need to be vaccinated to obtain one who is immune. The 
closer the NNT is to 1; the more effective is the treatment. The crucial 
figure is our estimate of the efficacy expressed as a percentage. We 
have VE = [(1-RR) x100], where the VE is the vaccine efficacy. RR is 
the relative risk or risk ratio =(probability of an event in the exposed 
group)/(probability of the event in not exposed group).10 We also need 
to allow for uncertainty in our findings, expressed by the confidence 
interval. Vaccine A’s efficacy is 95% whereas vaccine B’s is 90%, 
which indicates that Vaccine A is more effective than vaccine B. The 
difference in their efficacy is 5%, corresponding to the extra 5 patients 
infected in the vaccine B group in our example. 
What does “efficacy” mean in practice?
 It is important to note that efficacy is not the proportion of the 
population who avoid infection but rather the reduction in the risk 
that they would face if unvaccinated. Table 2 shows that 100 out of 
150 would get the infection without the vaccine. In contrast, this was 
reduced to 5 out of 150 by vaccine A where the risk of 2/3 (100/150) 
was reduced to 1/30 (5/150), a proportionate reduction by 95%. 
Similar reasoning applies to Table 3.
Table 2 Vaccine A 95% efficacy versus placebo
Main equation
Infected Not-infected Total 
Vaccinated a b a+b
Not vaccinated c d c+d
Total a+c b+d Total
Application
Infected Not-infected Total
COVID-19 Vaccine 5 145 150
Placebo 100 50 150
Total 105 195 300
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Main equation
Calculation 
Control event rate c/(c+d) CER 0.67
Experimental event rate a/(a+b) EER 0.03
Relative Risk EER/CER RR 0.05
Absolute risk reduction CER-EER ARR 0.63
Number needed to treat 1/ARR NNT 1.58
Efficacy %=(1-RR) x100 95
 (95% CI) (88.1-97.9)
Table 3 Vaccine B 90% efficacy versus placebo
Main equation
Infected Not-infected Total 
Vaccinated a b a+b
Not vaccinated c d c+d
Total a+c b+d Total
Application
Infected Not-infected Total
COVID-19 Vaccine 10 140 150
Placebo 100 50 150
Total 110 190 300
Calculation
Control event rate c/(c+d) CER 0.67
Experimental event rate a/(a+b) EER 0.07
Relative Risk EER/CER RR 0.1
Absolute risk reduction CER-EER ARR 0.6
Number needed to treat 1/ARR NNT 1.67
%=(1-RR) x100 Efficacy% 90
 (95% CI) (81.6-94.6)
Table Continued...
Comparing efficacies
In comparing vaccines A and B, the number of infected patients 
using vaccine A is half of the number of patients treated with vaccine 
B, but A’s efficacy – the relative reduction in risk that it achieves – is 
not double that of B, but only 5% higher. 
Conclusion
The COVID-19 pandemic is having a substantial impact on health 
care and the socioeconomic aspects of people lives. Vaccines appear 
the most promising solution to the pandemic. The vaccine efficacy is 
largely debated in peer-review journals and by the media. This article 
provides a practical guide for students and health care professionals, 
using two examples with formulae to calculate the vaccine efficacy. 
It explains using facts and figures the confidence interval’s relevance 
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